{
    "Trade/Device Name(s)": [
        "Olympus Triglyceride Reagent",
        "Olympus Triglyceride OSR6x118",
        "Olympus Triglyceride Test System"
    ],
    "Submitter Information": "Olympus America, Inc.",
    "510(k) Number": "K063804",
    "Predicate Device Reference 510(k) Number(s)": [
        "K961274"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CDT"
    ],
    "Summary Letter Date": "March 23, 2007",
    "Summary Letter Received Date": "March 19, 2007",
    "Submission Date": "March 16, 2007",
    "Regulation Number(s)": [
        "21CFR862.1705"
    ],
    "Regulation Name(s)": [
        "Triglyceride test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Triglyceride"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "OLYMPUS analyzers",
        "AU400",
        "AU400e",
        "AU600",
        "AU640",
        "AU640e",
        "AU2700",
        "AU5400"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic GPO methodology with Trinder indicator system",
        "Enzymatic endpoint"
    ],
    "Methodologies": [
        "Enzymatic assay"
    ],
    "Submission Type(s)": [
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Olympus Triglyceride Reagent for quantitative determination of triglyceride concentrations in human serum and plasma using enzymatic endpoint methodology on Olympus analyzers",
    "Indications for Use Summary": "System reagent for quantitative determination of triglyceride concentrations in serum and plasma on OLYMPUS analyzers; used in diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other lipid metabolism diseases, endocrine disorders, and assessment of risk factors for atherosclerosis and coronary artery disease",
    "fda_folder": "Clinical Chemistry"
}